Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$30.10
-$0.20(-0.70%)
At close: 4:00 PM EST
$30.10
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.32
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.92M
Market Cap
$5.02B
Enterprise Value$4.45B
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$70.00M
Price to Earnings (P/E)21.0
Beta0.76
Next Earnings
Apr 29, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding166,649,930
10 Day Avg. Volume1,848,981
30 Day Avg. Volume1,916,018
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio8.85K
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda13.45
Forecast
1Y Price Target
$44.30Price Target Upside47.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.94
Revenue Forecast (FY)$1.79B
Bulls Say, Bears Say
Bulls Say
Clinical Development And Regulatory AlignmentAnalyst indicates regulators aligned on the orexin pivotal trial design, which follows established standards and reduces development and regulatory uncertainty for the narcolepsy program.
Management Continuity And Portfolio ExpansionAnalyst expects a seamless CEO succession to a long-tenured internal executive and notes the Avadel acquisition adds a product with substantial peak sales potential, enhancing long-term revenue prospects.
Product Commercial AdoptionAnalyst highlights Lumryz's once-nightly dosing and favorable payer coverage supporting continued market uptake, while Aristada's broader prescriber adoption strengthens psychiatry portfolio revenues.
Bears Say
Competitive PressuresAnalyst cautions that strong competition from established branded products and generics could limit Lumryz's ultimate market share and slow adoption of oxybate for idiopathic hypersomnia.
Leverage And Nonrecurring Revenue EffectsAnalyst notes the recent transaction meaningfully increases company leverage and that a one-time Medicaid-related gross-to-net favorability contributed to revenue, implying part of the improvement may not be recurring and elevating financial risk.
Revenue Guidance And Operating CostsAnalyst warns that lowered revenue guidance driven by softer Lybalvi sales and rising operating expenses points to weaker near-term financial performance and modest downward forecast revisions.
Alkermes News
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $25.16 and its highest was $36.32 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is $5.02B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Apr 29, 2026 which is in 59 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Feb 25, 2026. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.41 by -$0.12.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is -0.25.
How many shares outstanding does Alkermes have?
Alkermes has 166,649,930 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.29 in its last earnings report, missing expectations of $0.41. Following the earnings report the stock price went down -7.038%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.30 (47.18% Upside)
$44.30 (47.18% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.57%
12-Months-Change
Fundamentals
Return on Equity
14.72%
Trailing 12-Months
Asset Growth
23.09%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by strong 2025 commercial performance (9% growth in proprietary portfolio), solid profitability and cash position, strategic acquisition of Avadel to enter sleep medicine (LUMRIZE), and clear pipeline momentum (elixorexant breakthrough designation and Phase 3 start). Key near‑term headwinds are acquisition accounting effects (inventory step‑up and amortization) producing an expected GAAP loss in 2026, materially higher R&D and SG&A to fund growth and integration, and financing‑related interest expense and debt. Management provided detailed 2026 guidance showing healthy adjusted EBITDA and revenue expansion, while acknowledging payer/competitive risks in the oxybate market and potential VIVITROL dynamics in 2027.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$44.30
▲(47.18% Upside)
Technical Analysis
Ownership Overview
1.49% Insiders
28.24% Mutual Funds
6.62% Other Institutional Investors
29.78% Public Companies and
Individual Investors